Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

33%

Ph phase_3

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution2 total trials

Phase 2Efficacy & side effects

1(50.0%)

Phase 3Large-scale testing

1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(1)

Other(1)

Detailed Status

unknown1

Completed1

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 21 (50.0%)

Phase 31 (50.0%)

Trials by Status

unknown133%

completed133%

not_yet_recruiting133%

Recent Activity

0 active trials

Showing 3 of 3

unknown

Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition

NCT07332338

not_yet_recruitingphase_3

A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition

NCT07184385

completedphase_2

Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome

NCT05682560

Clinical Trials (3)

Showing 3 of 3 trials

NCT07332338

Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition

Unknown

NCT07184385Phase 3

A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition

Not Yet Recruiting

NCT05682560Phase 2

Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome

Completed

All 3 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 3